Keith A. Goldan - Feb 7, 2024 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Financial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 7, 2024
Transactions value $
$1,595,827
Form type
4
Date filed
2/9/2024, 04:05 PM
Previous filing
Jun 14, 2023
Next filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $15.6K +862 +32.8% $18.12 3.49K Jul 31, 2023 Direct F1
transaction SNDX Common Stock Other $20.6K +1.18K +33.9% $17.42 4.67K Jan 31, 2024 Direct F2
transaction SNDX Common Stock Award $0 +35K +748.98% $0.00 39.7K Feb 7, 2024 Direct F3
transaction SNDX Common Stock Award $0 +11.7K +29.49% $0.00 51.4K Feb 7, 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $1.56M +70K $22.28 70K Feb 7, 2024 Common Stock 70K $22.28 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 862 shares by the Reporting Person on 07/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,183 shares by the Reporting Person on 01/31/2024 pursuant to the Issuer's Employee Stock Purchase Plan.
F3 Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
F4 Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
F5 1/48th of the shares subject to the option shall vest monthly over a four-year period.